Description: Medexus Pharmaceuticals Inc, formerly Pediapharm Inc, is a Canada-based company engaged in pharmaceutical business sector. The Company is a North American focused, specialty pharmaceutical business that operates through three segments: Medac Pharma USA, a fully integrated commercial infrastructure focused on auto-immune diseases in the United States; Medexus Pharma Canada, a fully integrated commercial infrastructure focused on auto-immune disease and pediatric diseases in Canada; and a Business Development function, which works to maintain its product pipeline. The Company's flag products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an allergy medication. The Company provides products for the healthcare professionals and patients.
Home Page: www.medexus.com
MDP Technical Analysis
1 Place du Commerce
Verdun,
QC
H3E 1A2
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Kenneth d'Entremont | CEO & Director |
| Mr. Roland Boivin | Chief Financial Officer |
| Mr. Bill Poncy | Sr. VP of Commercial Operations - United States |
| Mr. Brian Peters | VP of Sales & Marketing - United States |
| Ms. Tina Byers CFA | Exec. of Investor Relations |
| Mr. Michael Pine | Sr. VP of Bus. Devel. & Strategy |
| Mr. Michael David Adelman | Gen. Mang., U.S. Operations |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 135.1351 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.0192 |
| Price-to-Sales TTM: | 1.0795 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |